Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5)

Robbin Itzler, Gary Koch, David O Matson, Leif Gothefors, Pierre Van Damme, Mark J Dinubile, Penny M Heaton, Robbin Itzler, Gary Koch, David O Matson, Leif Gothefors, Pierre Van Damme, Mark J Dinubile, Penny M Heaton

Abstract

Background: The Rotavirus Efficacy and Safety Trial was a placebo-controlled Phase III study that evaluated the safety and efficacy of a three-dose pentavalent rotavirus vaccine (RV5) including its effect on healthcare utilization for rotavirus gastroenteritis (RVGE). The per-protocol (PP) analyses, which counted events occurring 14 days after dose 3 among infants without protocol violations, have already been published. This paper evaluates the consistency of the healthcare utilization results based on the modified intention to treat (MITT) analyses with the PP analyses. The MITT analyses include all infants receiving at least one dose of vaccine or placebo and follow-up begins after dose 1. The paper also explores the consistency of the results for different subgroups of the study population with different types of surveillance.

Methods: Data on healthcare utilization for acute gastroenteritis were collected via telephone interviews after administration of the first dose. Parents were either contacted every 6 weeks or every 2 weeks depending on the substudy in which they were enrolled. Those contacted every 2 weeks were also asked to complete symptom diaries. Poisson regression was used to evaluate the effect of RV5 on the rates of RVGE-associated healthcare encounters in all of the analyses.

Results: In the first 2 years after vaccination, RV5 reduced the combined rate of hospitalizations and emergency department (ED) visits 88.9% (95% CI: 84.9, 91.9) for all RVGE regardless of serotype in the MITT analysis compared with a 94.5% (95% CI: 91.2, 96.6) reduction based on the G1-G4 PP analysis. By type of surveillance, the rate reductions for the G1-G4 PP analysis were 91.0% (95% CI: 81.7, 95.5) and 95.9% (95% CI: 92.2, 97.8) among parents contacted every 2 weeks (number evaluable = 4,451) and every 6 weeks (number evaluable = 52,683) respectively.

Conclusions: Our analyses demonstrated that the effect of RV5 on reducing the rate of hospitalizations and ED visits based on the MITT analyses were generally consistent with the PP analyses. The rate of events for subgroups with different intensities of surveillance differed but the effect of RV5 on the relative rate reductions were consistent with the results that have already been published.

Trial registration: ClinicalTrials.gov number, NCT00090233.

Figures

Figure 1
Figure 1
REST Study Design with Respect to the Collection of the Healthcare Utilization Data. N = number vaccinated.
Figure 2
Figure 2
Subject Accounting for MITT Analyses. There were no health care encounters on the first day of vaccination among 26 infants without follow-up after the first day of vaccination.

References

    1. Parashar UD, Alexander JP, Glass RI. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR. 2006;50(RR-12):1–16.
    1. Giaquinto C, Van Damme P, Huet F, Gothefors L, Maxwell M, Todd P, da Dalt L. Clinical consequences of rotavirus gastroenteritis in Europe, 2004-2005: the REVEAL study. J Infect Dis. 2007;195:S26–S35. doi: 10.1086/516717.
    1. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis. 2003;9:565–572.
    1. Glass RI, Lew JF, Gangarosa RE, LeBaron CW, Ho MS. Estimates of morbidity and mortality rates for diarrheal diseases in American children. J Pediatrics. 1991;118:S27–S33. doi: 10.1016/S0022-3476(05)81422-2.
    1. American Academy of Pediatrics: Provisional Committee on Quality Improvement, Subcommittee on Acute Gastroenteritis. Practice parameter: the management of acute gastroenteritis in young children. Pediatr. 1996;97:424–436.
    1. Ozuah PO, Avner JR, Stein REK. Oral rehydration, emergency physicians, and practice patterns: a national survey. Pediatr. 2002;109:259–261. doi: 10.1542/peds.109.2.259.
    1. LeBaron CW, Lew J, Glass RI, Weber JM, Ruiz-Palacios GM. Annual rotavirus epidemic patterns in North America: results of a 5-year retrospective survey of 88 centers in Canada, Mexico, and the United States. JAMA. 1990;264:983–8. doi: 10.1001/jama.264.8.983.
    1. Turcios RM, Curns AT, Holman RC, Pandya-Smith I, LaMonte A, Bresee JS, Glass RI. Temporal and geographic trends of rotavirus activity in the United States, 1997-2004. Ped Infect Dis J. 2006;25:451–4. doi: 10.1097/01.inf.0000214987.67522.78.
    1. Centers for Disease Control. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory committee on Immunization Practices (ACIP) MMWR. 2009;58:RR2.
    1. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PMl. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354:23–33. doi: 10.1056/NEJMoa052664.
    1. Ruiz-Palacios GM, Perez-Schael I, Velazquez RF, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, Cervantes Y, Linhares AC, López P, Macías-Parra M, Ortega-Barría E, Richardson V, Rivera-Medina DM, Rivera L, Salinas B, Pavía-Ruz N, Salmerón J, Rüttimann R, Tinoco JC, Rubio P, Nuñez E, Guerrero ML, Yarzábal JP, Damaso S, Tornieporth N, Sáez-Llorens X, Vergara RF, Vesikari T, Bouckenooghe A, Clemens R, De Vos B, O'Ryan M. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354:11–22. doi: 10.1056/NEJMoa052434.
    1. Vesikari T, Clark HF, Offitt PA, Dallas MJ, DiStefano DJ, Goveia MG, Ward RL, Schödel F, Karvonen A, Drummond JE, DiNubile MJ, Heaton PM. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety, and immunogenicity in healthy infants. Vaccine. 2006;24:4821–4829. doi: 10.1016/j.vaccine.2006.03.025.
    1. Block SL, Vesikari T, Goveia MG, Rivers SB, Adeyi BA, Dallas MJ, Bauder J, Boslego JW, Heaton PM. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatr. 2007;119:11–18. doi: 10.1542/peds.2006-2058.
    1. Parashar UD, Glass R. Rotavirus vaccines - early success, remaining questions. N Engl J Med. 2009;360:1063–1065. doi: 10.1056/NEJMp0810154.
    1. Tate JE, Panozzo CA, Payne DC, Patel MM, Cortese MM, Fowlkes AL, Parashar UD. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatr. 2009;124:465–471. doi: 10.1542/peds.2008-3528.
    1. Clark HF, Lawley D, Mallette L, DiNubile M. Decline in cases of rotavirus gastroenteritis presenting to Children's Hospital of Philadelphia after introduction of a pentavalent rotavirus vaccine. Clin Vaccine Immunol. 2009;16:382–386. doi: 10.1128/CVI.00382-08.
    1. Daskalaki I, Wood SJ, Inumerable YM, Long SS. Epidemiology of rotavirus-associated hospitalizations pre- and post-implementation of immunization: North Philadelphia, 2000-2008. Infectious Disease Society of America Conference; 25-28 October, 2008; Washington D.C.
    1. Mast T, Wang F, Goli V, Loughlin J, Bulotsky M, Seeger J. Post-licensure effectiveness of RotaTeq in preventing gastroenteritis. Infectious Disease Society Conference; 25-28 October 2008, Washington, D.C.
    1. Patel JA, Loeffelholz M. Reduction of severe rotavirus gastroenteritis following the routine use of live, oral, pentavalent rotavirus vaccine. Infectious Disease Society of America Conference, 25-28 October 2008, Washington, D.C.
    1. Vesikari T, Itzler R, Matson DO, Santosham M, Christie CD, Coia M, Cook JR, Koch G, Heaton P. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries) Int J Infect Dis. 2007;11(Suppl 2):S29–35. doi: 10.1016/S1201-9712(07)60019-8.
    1. Sloan FA. Valuing health care: costs, benefits, and effectiveness of pharmaceuticals and other medical technologies. Cambridge University Press. 1995.
    1. Mato SP, Perrin K, Scardino D, Begue RE. Evaluation of rotavirus vaccine effectiveness in a pediatric group practice. Am J of Epidemiol. 2002;156:1049–55. doi: 10.1093/aje/kwf146.
    1. DiStefano DJ, Kraiouchkine N, Mallette L, Maliga M, Kulnis G, Keller PM, Clark HF, Shaw AR. Novel rotavirus VP7 typing assay using a one-step reverse transcriptase PCR protocol and product sequencing and utility of the assay for epidemiological studies and strain characterization, including serotype subgroup analysis. J Clin Microbiol. 2005;43:5876–5880. doi: 10.1128/JCM.43.12.5876-5880.2005.
    1. Zeger SL, Liang K-Y, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44:1049–1060. doi: 10.2307/2531734.
    1. Stokes ME, Davis CS, Koch GG. In: Categorical data analysis using the SAS® system. 2. Stokes ME, Davis CS, Koch GG, editor. North Carolina: SAS Institute, Inc; 2000.
    1. Jovanovic BD, Zalenski RJ. Safety evaluation and confidence intervals when the number of observed events is small or zero. Ann Emerg Med. 1997;30:301–306. doi: 10.1016/S0196-0644(97)70165-3.
    1. Ciarlet M, Schodel F. Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq®. Vaccine. 2009;27S:G72–G81. doi: 10.1016/j.vaccine.2009.09.107.
    1. Goveia MG, Rodriguez ZM, Dallas MJ, Itzler RF, Boslego JW, Heaton PM, DiNubile MJ. Safety and Efficacy of the Pentavalent Human-Bovine (WC3) Reassortant Rotavirus Vaccine in Healthy Premature Infants. Ped Inf Dis J. 2007;26:1099–1104. doi: 10.1097/INF.0b013e31814521cb.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner